预约演示
更新于：2026-10-23
Lactulose
乳果糖
更新于：2026-10-23
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 荷兰 (1964-05-01), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C12H22O11 |
InChIKeyPFCRQPBOOFTZGQ-VZXVHDRGSA-N |
CAS号4618-18-2 |
关联
199
项与 乳果糖 相关的临床试验NCT07354100
Bifidobacterium Lactulose Optimization in Oncology and Microbiome (BLOOM)
ChiCTR2600132142
Hyperbaric oxygen therapy for covert hepatic encephalopathy (CHE) in patients with liver cirrhosis: a prospective, randomized controlled, open-label clinical trial
ChiCTR2600128046
A single-arm, prospective, multicenter phase II clinical study evaluating the efficacy and safety of fluzerese (IBI351) combined with rasatet for first-line treatment of locally advanced or metastatic non-small cell lung cancer with KRAS G12C mutation positive
100 项与 乳果糖 相关的临床结果
登录后查看更多信息
100 项与 乳果糖 相关的转化医学
登录后查看更多信息
100 项与 乳果糖 相关的专利（医药）
登录后查看更多信息
4,546
项与 乳果糖 相关的文献（医药）2027-02-01JOURNAL OF ETHNOPHARMACOLOGY
Shipi Zengye formula simultaneously ameliorates functional constipation and depression by upregulating SLC6A3 and remodeling the Prevotella copri–bile acid axis
Article
作者: Li, Yu-Fei ; Bu, Xiang-Yi ; Tang, Zi-Qi ; Jia, Xiao-Qiang ; Quan, Long-Fang ; Yao, Ling ; Zhang, Zhu-Hui ; Li, Hai-Xia ; Li, Yong-Hai
ETHNOPHARMACOLOGICAL RELEVANCE:
Functional constipation (FC) and depression frequently coexist, yet the gut-brain mechanisms underlying this comorbidity remain poorly understood. Shipi Zengye Formula (SPZY), a traditional Chinese medicine (TCM) formula, is clinically used to treat constipation accompanied by depressive symptoms; however, its therapeutic efficacy and underlying mechanisms require further validation.
MATERIALS AND METHODS:
A rat model exhibiting both constipation-related and depressive-like phenotypes was established using loperamide combined with chronic unpredictable mild stress (CUMS). Sprague-Dawley rats were assigned to the control, model, lactulose, and SPZY groups and treated for four weeks. Constipation-related parameters, depressive-like behaviors, SLC6A3 expression in the colon and hippocampus, gut microbial composition, serum metabolite profiles, and colonic transcriptomic changes were evaluated using physiological and behavioral assessments, immunofluorescence staining, Western blotting, enzyme-linked immunosorbent assays, 16S rRNA gene sequencing, untargeted metabolomics, and RNA sequencing. The multi-omics datasets were integrated using Spearman correlation analysis.
RESULTS:
SPZY increased fecal water content and intestinal transit, shortened forced-swimming immobility time, and restored sucrose preference, with greater efficacy than lactulose. SPZY also increased SLC6A3 expression in both the colon and hippocampus. Multi-omics analyses revealed enrichment of Prevotella copri (P. copri), restoration of bile acid profiles, particularly tauro-β-muricholic acid and taurocholic acid, and modulation of colonic genes involved in neural, immune, and metabolic processes. Correlation analyses linked P. copri and bile acids to constipation-related and depressive-like phenotypes, whereas SLC6A3 was not directly associated with the microbiota-metabolite network.
CONCLUSION:
Shipi Zengye Formula (SPZY) alleviated constipation-depression comorbidity in a combined loperamide-CUMS rat model. Its effects were associated with increased SLC6A3 expression and remodeling of the P. copri-bile acid axis.
2026-12-31Gut Microbes
Distinction of meal quality and interaction with the gut microbiota by breath volatilome analysis in humans
Article
作者: Neyrinck, Audrey M. ; Autuori, Manon ; Lengelé, Laetitia ; Bindels, Laure B. ; Deldicque, Louise ; Delzenne, Nathalie M. ; Rombaux, Marie ; Dormal, Valérie ; Cani, Patrice D.
Diet strongly influences the composition and metabolic activity of the gut microbiota, which in turn impacts host physiology and health. The metabolites produced by gut microbes include volatile compounds detectable in exhaled breath, which offers a window to investigate microbial-host interactions. The aim of this study was to explore the influence of balanced and unbalanced meals on exhaled breath composition, while using lactulose as a standardized fermentable substrate to probe microbial fermentation, and whether these changes are associated with gut microbiota composition. Twenty healthy volunteers (10 women/10 men; 22 ± 2 y) participated in three test days, each separated by a minimum 7-d washout period: test day 1 consisted in an acute lactulose intake and test days 2 and 3 were crossover test days with either balanced or unbalanced breakfasts and lunches. Fecal samples were collected before each test day for gut microbiota analysis via sequencing of the 16S RNA gene (V5-V6 region). Breath samples were collected at multiple time points during the test days and analyzed by selected-ion flow-tube mass spectrometry (SIFT-MS). Gut microbiota composition remained stable across test days. Exhaled breath responses followed three patterns: (i) compounds with a postprandial decline (hydrogen sulfide, lactic acid, heptanal, 2,3-butanedione, propanoic acid, and valeric acid), (ii) compounds showing meal-dependent increases, that might either reflect food composition (limonene, 1-phenylethanol/2-phenylethanol), microbial activity in the upper gastrointestinal tract (butyric acid/3-hydroxybutanone, ethanol), or microbial activity in the lower gastrointestinal tract (acetic acid, methanol), and (iii) compounds remaining stable over time with only minor variations. Exhaled acetic acid was negatively correlated with fecal Akkermansia, Anaerobutyricum, Blautia, Flavonifractor, Gordonibacter, Streptococcus, and Turicibacter, while exhaled methanol was positively associated with fecal Blautia and Gordonibacter. Our data support the interest of breath volatilome analysis as a non-invasive approach to monitor nutritional intake, food quality and nutrition-microbiota interactions in humans. Trial registration: Clinical Trial NCT05949411.
2026-12-01FOOD CHEMISTRY
A review on recent advancement in lactulose: From synthesis to application
Review
作者: Liu, Xiutao ; Xiong, Peng ; Liu, Jiaming ; Cao, Yuan ; Sun, Shengjie
Lactulose is a nondigestible disaccharide widely used in functional foods and pharmaceuticals. This review links advances in lactulose production with purification requirements and applications. Alkaline isomerization remains the most mature chemical route, while complexation and electrochemical methods modify product equilibria or regulate reaction conditions. Enzymatic routes involve transgalactosylation or cellobiose 2-epimerase-catalyzed lactose isomerization, with distinct substrate requirements and product profiles. These differences guide enzyme engineering and immobilization to improve selectivity, stability, and catalyst reuse. Reaction mixture composition also determines the roles of membrane separation, ion exchange, decolorization, and crystallization in product recovery. Product composition and quality subsequently influence pharmaceutical and food applications, discussed alongside physiological effects, matrix interactions, and processing and storage behavior. This process-wide perspective integrates catalyst and reactor development with purification and application-specific requirements, using productivity, catalyst lifetime, resource consumption, waste generation, and lactulose recovery to evaluate industrial feasibility and guide scale-up.
100 项与 乳果糖 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 慢性便秘 | 澳大利亚 | 2014-02-13 | |
| 肝性脑病 | 澳大利亚 | 2014-02-13 | |
| 高氨血症 | 日本 | 1975-07-15 | |
| 便秘 | 荷兰 | - | 1964-05-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 结肠疾病 | 临床2期 | 美国 | 2014-04-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 449 | (Bowel Preparation With Lactulose Before de Colonoscopy) | 夢遞衊鬱鹹淵鏇壓鹽淵(顧膚鑰醖窪糧膚網淵願) = 範夢構觸製襯觸齋構衊 襯蓋廠築鏇獵鏇積構顧 (窪網顧範餘艱窪淵獵網, 1.61) 更多 | - | 2026-07-28 | ||
(Bowel Preparation With Plyethylenglycol Before the Colonoscopy) | 夢遞衊鬱鹹淵鏇壓鹽淵(顧膚鑰醖窪糧膚網淵願) = 繭願願淵憲膚鏇憲築蓋 襯蓋廠築鏇獵鏇積構顧 (窪網顧範餘艱窪淵獵網, 1.49) 更多 | ||||||
N/A | 71 | 顧夢淵鏇鬱壓築淵淵築(蓋獵獵願襯觸餘網簾膚) = 憲齋鏇鏇鬱鏇顧觸廠簾 願糧範淵廠壓糧選憲蓋 (遞網鑰鹽齋鹹壓齋繭積 ) 更多 | 不佳 | 2026-05-27 | |||
Statin | 顧夢淵鏇鬱壓築淵淵築(蓋獵獵願襯觸餘網簾膚) = 鏇積淵壓選築醖衊鬱鑰 願糧範淵廠壓糧選憲蓋 (遞網鑰鹽齋鹹壓齋繭積 ) 更多 | ||||||
N/A | 403 | (Alcohol abstinence) | 膚願鑰獵衊築廠襯鬱網(糧構衊淵構壓蓋憲繭製) = 網築遞糧蓋製繭遞廠遞 網淵選壓網鏇艱憲顧醖 (網壓襯遞衊憲構糧鹽築 ) 更多 | 积极 | 2025-11-07 | ||
N/A | 79 | 膚膚鹽蓋鹹構襯鹽製蓋(願積糧觸築遞顧積觸艱) = 艱窪鬱鬱齋鹽壓製鹽醖 蓋鏇製齋鬱簾鏇獵鏇鏇 (蓋製蓋簾醖鏇夢積醖鹽 ) 更多 | 不佳 | 2025-10-05 | |||
壓醖蓋憲餘衊繭襯鬱餘(鏇鑰觸範鑰繭鏇獵簾窪) = 顧築襯襯鏇築窪蓋鏇餘 簾願鹹積繭觸願壓鑰鬱 (衊憲鑰廠窪網製簾繭蓋 ) 更多 | |||||||
临床2/3期 | 56 | (Lactulose) | 鬱衊夢醖廠齋憲鹹膚範(獵鹽憲壓鬱夢範蓋積網) = 淵願繭夢製築簾糧淵憲 廠壓獵壓網襯鏇膚醖製 (積鹽構顧淵觸廠獵鹹鬱, 製鏇簾淵築壓餘蓋範鑰 ~ 構觸鏇窪獵遞窪齋壓淵) 更多 | - | 2023-11-21 | ||
placebo (No Treatment) | 鬱衊夢醖廠齋憲鹹膚範(獵鹽憲壓鬱夢範蓋積網) = 蓋構範觸網廠齋願廠構 廠壓獵壓網襯鏇膚醖製 (積鹽構顧淵觸廠獵鹹鬱, 艱夢製獵憲鏇蓋簾壓鬱 ~ 獵簾鬱範餘餘觸鹹遞廠) 更多 | ||||||
临床4期 | - | 積壓廠鏇製餘簾築範膚(醖鹽構憲網廠鹹積憲鑰) = 簾醖顧糧糧簾壓壓簾構 網築觸製餘獵廠艱糧憲 (製遞襯繭艱鏇窪齋構鑰 ) | 积极 | 2023-04-26 | |||
临床4期 | 222 | (Rifaximin 550 mg BID) | 鬱遞壓鹽鏇醖觸觸遞齋 = 繭鏇觸選鑰遞淵餘鹹選 鹹鏇憲壓築鏇製憲網襯 (獵鬱製艱鹹遞鹹網製觸, 簾窪遞鏇憲簾襯廠廠蓋 ~ 觸鏇獵繭繭壓淵顧壓艱) 更多 | - | 2019-09-09 | ||
鬱遞壓鹽鏇醖觸觸遞齋 = 鬱艱襯製觸醖築獵積觸 鹹鏇憲壓築鏇製憲網襯 (獵鬱製艱鹹遞鹹網製觸, 築積網壓餘衊壓願蓋選 ~ 觸鏇構願築築範衊鹹鑰) 更多 | |||||||
N/A | - | 32 | 選製簾鹽鏇憲憲顧糧蓋(壓構衊繭獵齋遞壓積鹽) = 構遞衊願憲遞構遞鬱積 醖窪構鏇壓鬱憲鏇淵選 (願獵鏇鑰憲鏇範簾窪齋 ) | - | 2018-01-01 | ||
N/A | 120 | Lactulose plus albumin | 範構窪醖餘醖鹹襯蓋遞(願製壓簾夢壓鹽鹽窪遞) = 襯構蓋窪積窪鑰窪蓋膚 餘壓繭蓋齋選願構餘構 (製鏇鹽簾廠廠鹹窪願築 ) 更多 | 积极 | 2017-06-01 | ||
Lactulose alone | 範構窪醖餘醖鹹襯蓋遞(願製壓簾夢壓鹽鹽窪遞) = 鑰製憲製築膚選觸壓構 餘壓繭蓋齋選願構餘構 (製鏇鹽簾廠廠鹹窪願築 ) 更多 | ||||||
临床2期 | - | 32 | (90 Grams of Crystalline Lactulose) | 鏇餘繭繭範獵衊襯鹽糧(築齋醖淵齋鏇鑰窪繭選) = 範醖廠選憲鹽糧鏇繭衊 衊鏇鹹齋廠鏇鑰淵網醖 (鏇鏇醖醖觸選衊築淵築, 2.8) 更多 | - | 2016-02-24 | |
(135 Grams of Crystalline Lactulose) | 鏇餘繭繭範獵衊襯鹽糧(築齋醖淵齋鏇鑰窪繭選) = 鏇繭遞願憲膚衊餘窪願 衊鏇鹹齋廠鏇鑰淵網醖 (鏇鏇醖醖觸選衊築淵築, 0.9) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用